Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) have been assigned an average recommendation of “Buy” from the ten research firms that are currently covering the company, Marketbeat reports. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $52.14.
Several research analysts have recently weighed in on DNTH shares. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Guggenheim reaffirmed a “buy” rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Raymond James raised shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, TD Cowen began coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They issued a “buy” rating on the stock.
Institutional Inflows and Outflows
Dianthus Therapeutics Price Performance
NASDAQ:DNTH opened at $21.33 on Wednesday. The company has a market cap of $631.30 million, a P/E ratio of -8.53 and a beta of 1.82. The stock’s fifty day moving average price is $22.54 and its two-hundred day moving average price is $24.81. Dianthus Therapeutics has a 1 year low of $18.13 and a 1 year high of $33.77.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.04. The firm had revenue of $1.33 million for the quarter, compared to analysts’ expectations of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current fiscal year.
Dianthus Therapeutics Company Profile
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Featured Stories
- Five stocks we like better than Dianthus Therapeutics
- Trading Stocks: RSI and Why it’s Useful
- How to Build the Ultimate Everything ETF Portfolio
- How to Invest in Insurance Companies: A GuideĀ
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Best Stocks Under $5.00
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.